by Clinical Neuropsychologist Online | Monday, October 12, 2026 | Neuroscience
Nature Neuroscience, Published online: 12 October 2026; doi:10.1038/s41593-026-02481-zThis study identifies common structural variants contributing to Alzheimer’s disease heritability. An expanded promoter CCG repeat increases FAM193B expression and disease risk,...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION ApoE ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD). Emerging evidence suggests that ApoE4 increases AD risk by disrupting microglial metabolism and function. However, whether ApoE lipidation state contributes to...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Diabetes is associated with elevated risk of Alzheimer’s disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited,...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Cognitive composites offer greater sensitivity to amyloid beta (Aβ)-related decline compared to individual tests for tracking longitudinal cognitive change. We developed and validated data-driven composites from the harmonized Alzheimer’s...
by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia
Abstract INTRODUCTION Effective disease-modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms...
